Get the Stockscreener App
17.84
3.04%
-0.56
Trevi Therapeutics Inc stock is traded at $17.84, with a volume of 1.03M.
It is down -3.04% in the last 24 hours and up +33.13% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
See More
Previous Close:
$18.40
Open:
$18.32
24h Volume:
1.03M
Relative Volume:
0.55
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-45.61M
P/E Ratio:
-55.15
EPS:
-0.3235
Net Cash Flow:
$-45.40M
1W Performance:
-0.50%
1M Performance:
+33.13%
6M Performance:
+59.57%
1Y Performance:
+178.32%
1-Day Range:
$17.52
$18.33
1-Week Range:
$17.52
$20.15
52-Week Range:
$6.245
$20.15
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
17.84 | 2.53B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial - TipRanks
SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
TRVi stock stays tied to Trevi Therapeutics' clinical outlook - ad-hoc-news.de
Price to sales forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to book forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to earnings forward of Trevi Therapeutics, Inc. – BOATS:TRVI - TradingView
Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com - Investing.com South Africa
Trevi Therapeutics stock hits all-time high at 19.33 USD - Investing.com
$Trevi Therapeutics (TRVI.US)$ keep squeezing baby - Moomoo
Should Trevi’s Multi‑Index Russell Exit Reshape How Haduvio Drives the Trevi Therapeutics (TRVI) Story? - simplywall.st
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell Microcap Index - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Index - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23 - Moomoo
Trevi Therapeutics stock hits all-time high at 18.17 USD By Investing.com - Investing.com Australia
Trevi Therapeutics stock hits all-time high at 18.17 USD - Investing.com
Trevi Therapeutics, Inc. Actuals & Estimates (NASDAQ:TRVI) - TradingView
TRVI Forecast — Price Target — Prediction for 2027 - TradingView
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$Trevi Therapeutics (TRVI.US)$ finally you are getting squeezed - Moomoo
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trevi Therapeutics stock hits all-time high at 16.13 USD By Investing.com - Investing.com Nigeria
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Trevi Therapeutics Announces Upcoming June and July Event Schedule - GlobeNewswire
Trevi Therapeutics stock hits all-time high at 16.13 USD - Investing.com
Trevi Therapeutics Slides As Hot Biotech Rally Cools - TipRanks
Trevi Therapeutics (TRVI) Surges 5.05% as Momentum Builds Near ResistanceBox Spread - dars.gov.et
128,306,056 Common Stock of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
TRVI Q1 2026 Earnings: Clinical Progress Drives Stock Gains Despite EPS MissEarnings Call Q&A - newsline.com
Trevi Therapeutics Shareholders Approve Stock and Governance Changes - The Globe and Mail
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Trevi Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. - AOL.com
TRVI: All proposals passed, including share increase and director election, with no shareholder questions - TradingView
Pivotal bioVenture Partners Increases Trevi Therapeutics Holdings by 296,944 Shares in Q1 2026News and Statistics - IndexBox
Trevi Therapeutics stock hits 52-week low at 13.68 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week low at 13.68 USD - Investing.com
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):